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Abstract
Background: Several uncontrolled studies of hyperbaric treatment in children with autism have
reported clinical improvements; however, this treatment has not been evaluated to date with a
controlled study. We performed a multicenter, randomized, double-blind, controlled trial to assess
the efficacy of hyperbaric treatment in children with autism.
Methods: 62 children with autism recruited from 6 centers, ages 2–7 years (mean 4.92 ± 1.21),
were randomly assigned to 40 hourly treatments of either hyperbaric treatment at 1.3 atmosphere
(atm) and 24% oxygen ("treatment group", n = 33) or slightly pressurized room air at 1.03 atm and
21% oxygen ("control group", n = 29). Outcome measures included Clinical Global Impression
(CGI) scale, Aberrant Behavior Checklist (ABC), and Autism Treatment Evaluation Checklist
(ATEC).
Results: After 40 sessions, mean physician CGI scores significantly improved in the treatment
group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001),
social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment
group were rated as "very much improved" or "much improved" compared to 2/26 (8%) of controls
(p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls
(p = 0.0024). Mean parental CGI scores significantly improved in the treatment group compared
to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p
= 0.0322). On the ABC, significant improvements were observed in the treatment group in total
score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control
group. In the treatment group compared to the control group, mean changes on the ABC total
score and subscales were similar except a greater number of children improved in irritability (p =
0.0311). On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the
treatment group compared to the control group. Post-hoc analysis indicated that children over age
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5 and children with lower initial autism severity had the most robust improvements. Hyperbaric
treatment was safe and well-tolerated.
Conclusion: Children with autism who received hyperbaric treatment at 1.3 atm and 24% oxygen
for 40 hourly sessions had significant improvements in overall functioning, receptive language, social
interaction, eye contact, and sensory/cognitive awareness compared to children who received
slightly pressurized room air.
Trial Registration: clinicaltrials.gov NCT00335790
Background
Autistic Disorder (autism), along with Asperger syndrome
and pervasive developmental disorder–not otherwise
specified (PDD-NOS), comprise a spectrum of neurode-
velopmental disorders (collectively termed autism spec-
trum disorders or ASD) that are characterized by
restrictive and repetitive behaviors along with impair-
ments in communication and social interaction [1]. The
number of children diagnosed with ASD has increased
over the last decade [2-4] and ASD currently affects as
many as 1 out of 150 individuals in the United States
(U.S.) [5]. ASD is generally considered a "static" neurolog-
ical disorder [6] without any known cure. The use of
hyperbaric treatment in children with ASD has increased
in recent years [7] and traditionally involves inhaling up
to 100% oxygen at a pressure greater than one atmosphere
(atm) in a pressurized chamber [8]. Most typical indica-
tions for hyperbaric treatment involve the use of hyper-
baric pressures above 2.0 atm. Higher atmospheric
pressures are generally required to treat conditions such as
carbon monoxide poisoning and to improve wound heal-
ing [8,9]. However, improvements have been observed via
treatments with 95–100% oxygen and hyperbaric pres-
sures of 1.5–2.0 atm for some chronic neurological condi-
tions, including autism [7], fetal alcohol syndrome [10],
cerebral palsy [11,12], and chronic or traumatic brain
injury [13-16]. Furthermore, improvements in some of
these conditions, including autism [7,17] and cerebral
palsy [12], have been observed with the use of hyperbaric
pressures of 1.3 atm and oxygen levels of 21–24%. In one
study, significant improvements were observed in chil-
dren with autism with the use of hyperbaric treatment at
both 1.5 atm/100% oxygen and 1.3 atm/24% oxygen; nei-
ther hyperbaric protocol worsened markers of oxidative
stress and both reduced C-reactive protein (a marker of
inflammation) [7]. Rationales for the use of hyperbaric
treatment in autism include decreasing inflammation [18-
20], improving cerebral hypoperfusion [21,22], and mod-
ulating immune dysregulation [23-25], all reported as
problems in some individuals with autism [26-34]. Sev-
eral case reports [21,22] and three uncontrolled studies
enrolling between 6 and 18 children with autism
[7,17,35] have reported clinical improvements with
hyperbaric treatment at 1.3 atm. However, to our knowl-
edge, the efficacy of hyperbaric treatment in children with
autism has not been evaluated to date with a controlled
study. Given this background, we decided to study the
effects of hyperbaric treatment in children with autism
using 1.3 atm and 24% oxygen compared to near-placebo
hyperbaric conditions (slightly pressurized room air at
1.03 atm and 21% oxygen).
Hyperbaric treatment for children is generally regarded as
safe, even at pressures of 2.0 atm and 100% oxygen for
two hours per day [36]. In descending order, the most
common side effects observed during hyperbaric treat-
ment are barotrauma (2% incidence), sinus squeeze,
serous otitis, claustrophobia, reversible myopia, and new
onset seizure (which occurs in 1–3 per 10,000 treatments)
[8]. In children with autism, the use of hyperbaric treat-
ment using pressures up to 1.5 atm and 100% oxygen has
been shown to be safe and well-tolerated [7,17].
Methods
Study Design
This was a prospective, randomized, double-blind, con-
trolled trial involving treatment in parallel groups for 4
weeks. Active treatment was hyperbaric treatment at 1.3
atm and 24% oxygen for 40 sessions lasting 1 hour each
at pressure ("treatment group"), whereas the control treat-
ment consisted of slightly pressurized room air at 1.03
atm and 21% oxygen for 40 sessions lasting 1 hour each
at pressure ("control group"). Comparison of the clinical
effects of parallel treatments for 4 weeks was the primary
objective of this study. The number of treatments (40 ses-
sions) and the overall treatment period (4 weeks) were
chosen because these were previously shown to be safe in
two other studies of hyperbaric treatment in children with
autism [7,17].
Participants: Eligibility Criteria and Recruitment
This study was approved by the Liberty Institutional
Review Board and enrolled children, 2 to 7 years of age,
who had a diagnosis of Autistic Disorder and had not pre-
viously received any type of hyperbaric treatment. All chil-
dren met the DSM-IV criteria for Autistic Disorder [1] and
this diagnosis was also corroborated by psychologists
using the Autism Diagnostic Interview–Revised (ADI-R)
and the Autism Diagnostic Observation Schedule
(ADOS). Children with PDD-NOS, Asperger syndrome,BMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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seizure disorder, current ear infection, uncontrolled
asthma, inability to equalize ear pressure, fragile X syn-
drome, and ongoing treatment with chelation medication
were excluded from participation in this study. Written
informed consent was obtained from the parents and,
when possible, the child. Sixty-six children were evaluated
for inclusion in the study from six clinics throughout the
U.S. Four children were excluded from participation
because the diagnosis of Autistic Disorder could not be
corroborated by ADI-R and ADOS. Therefore, the recruit-
ment process yielded 62 eligible participants, who were
randomized as depicted in Figure 1.
Interventions
The active treatment was hyperbaric treatment at 1.3 atm
and 24% oxygen in a monoplace hyperbaric chamber for
60 minutes at this pressure per session (this length of time
did not include approximately 10–15 minutes for pressur-
ization and depressurization). Oxygen flowing at 10 liters
per minute from an oxygen concentrator was mixed with
room air and pumped into the chamber following a pro-
tocol previously described [7]. This resulted in a final
chamber oxygen concentration of approximately 24% as
measured by an oxygen monitor. This treatment was given
twice a day separated by a minimum of 4 hours, 5 days per
week, for 4 consecutive weeks, for a total of 40 treatments
per child.
Control treatment consisted of slightly pressurized room
air (1.03 atm and 21% oxygen) in a monoplace hyper-
baric chamber for 60 minutes at this pressure per session
(this length of time did not include approximately 10–15
minutes for pressurization and depressurization). This
treatment was given twice a day separated by a minimum
of 4 hours, 5 days per week, for 4 consecutive weeks, for a
total of 40 treatments per child. For blinding purposes,
Consolidated Standards of Reporting Trials (CONSORT) flow diagram Figure 1
Consolidated Standards of Reporting Trials (CONSORT) flow diagram.
66 children 
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4 excluded: 
not Autistic 
Disorder
62 randomized
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participants underwent a brief compression to 1.1 atm at
the beginning of each treatment. The chamber was then
slowly decompressed from 1.1 to 1.03 atm where the pres-
sure stayed for the remainder of the treatment. No oxygen
was added to the chamber and thus the chamber was pres-
surized with room air (approximately 21% oxygen). The
children in the control group remained in the chamber for
the same length of time as children in the treatment
group. At the end of each treatment, the pressure was
slowly increased to 1.1 atm over about 5 minutes and
then the chamber was depressurized. Procedures were
developed and applied to mimic, for the control group,
the experience of hyperbaric treatment at 1.3 atm, and
thereby to keep participants and parents unaware of the
nature of the intervention. These procedures included
covering control switches, inflating and deflating the
chambers to simulate pressure changes, and masking the
sounds from the chambers. To further mask the group
assignments, the equipment (including chambers) used
for the control group was indistinguishable from the
equipment used for the treatment group. Moreover, the
same type of equipment was used at each study site. A
pressure of 1.03 atm (with increases to 1.1 atm for several
minutes at the beginning and at the end of the treatment)
was chosen for the control group because this pressure
represented the lowest that could be applied and still
effectively simulate hyperbaric treatment at 1.3 atm. To
verify its effectiveness, prior to beginning the study, this
pressure protocol was tested in six adult individuals who
were randomly and repeatedly exposed to both the treat-
ment group pressure (1.3 atm) and the control group
pressure (1.03 atm with short increases to 1.1 atm) and
none of these individuals were able to reliably distinguish
between the two pressures. At each study site, the primary
investigator (DAR) visited and trained each hyperbaric
technician to ensure that the same protocol was followed
to minimize variances between study sites. An analysis
performed after the study was finished demonstrated no
significant differences (p = ns) between the six study sites
for age, initial autism severity, and initial and final scores
on all of the scales used in this study (this analysis can be
found in the results section).
Initial screening for this study included medical history
taking and a physical examination by one of the study
physicians. This included examination of the ears and
tympanic membranes. Throughout each treatment, chil-
dren were closely monitored by a hyperbaric technician
for any signs of ear pain or other problems, and parents
were instructed on how to recognize ear pain in their
child. In both groups, in order to facilitate treatments, a
parent or primary caretaker accompanied the child into
the chamber as it was deemed that the children were too
young to enter and remain in the chamber alone for the
duration of each treatment. Children finishing more than
one full session were included in the final analysis in an
intention-to-treat manner. Daily treatment logbooks for
each child were maintained by the hyperbaric technician
and any side effects during treatment were recorded. At
the end of the study, all children assigned to the control
group were offered 40 hyperbaric treatments at the treat-
ment pressure (1.3 atm and 24% oxygen) if the parents
desired (all parents chose this option; treatments were
provided without charge). During the study period, chil-
dren in both groups were not allowed to begin any new
therapies or stop any current therapies, including medica-
tions and nutritional supplementation. At the onset of the
study, the use of nutritional supplements, medications,
and applied behavioral analysis (ABA) therapy was simi-
lar in both the treatment and control groups (p = ns), see
Table 1.
Randomization and Allocation
From the 62 children who were enrolled in the study, 33
were randomly allocated to the treatment group and 29
were randomly allocated to the control group. To achieve
this allocation, a random allocation sequence (1:1) was
generated and stratified on both the participant's group
(treatment or control) and center, and this sequence was
equilibrated every eight patients. The allocation sequence
remained concealed to all investigators, study partici-
pants, parents, nursing staff, and all other clinic staff. The
only person at each center who was aware of the group
assignment for each particular child was the hyperbaric
technician, who had no input in the evaluation (outcome
measures) of the child. The hyperbaric technician was spe-
cifically instructed not to discuss the treatment nature or
group assignments with anyone else in the clinic, includ-
ing participants, parents, psychologists, and physicians. It
was not possible to blind the hyperbaric technician due to
the nature of the study (the technician had to know the
group assignment in order to adjust the chamber to the
correct pressure for treatment). However, all individuals
involved in evaluating the child (parents, physicians, and
psychologists) remained blinded to the group assignment
for each child throughout the entire study period. In
hyperbaric treatment studies, the study is considered dou-
ble-blinded if the study participants and the evaluators of
outcome measures are both blinded to group assignment
(as they were in this study), even though the hyperbaric
technician is aware of the assignment [37,38]. After the
study was completed, parents in both groups were sur-
veyed to determine the effectiveness of the blinding proc-
ess, and there was no significant difference between
groups in their ability to determine which group their
child had been assigned (p = ns).
Outcome measures
The primary outcome measures were changes compared
to baseline observed after 4 weeks (40 sessions) of treat-BMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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ment, in parallel groups, on (1) Aberrant Behavior Check-
list–Community (ABC) total score and subscale scores,
based on the parent's or primary caretaker's rating, (2)
Autism Treatment Evaluation Checklist (ATEC) total score
and subscale scores, based on the parent's or primary care-
taker's rating, and (3) Clinical Global Impression–
Improvement (CGI) scale for changes in overall function-
ing and subscales, as rated by the parent or primary care-
taker and also as rated separately by the treating physician
(without knowledge of the parental ratings).
Previous studies of hyperbaric treatment in children with
autism have utilized the ABC and/or ATEC [7,17]. The
ABC is a 58-item questionnaire that assesses communica-
tion, reciprocal social interaction, play, and stereotypical
behaviors [39]. It is used to evaluate the effectiveness of
medications and other therapeutic interventions and is
scored from 0 ("not at all a problem") to 3 ("problem is
severe in degree"). For this study, a total score was calcu-
lated as well as scores in 5 subscales: irritability, social
withdrawal (also termed lethargy), stereotypy, hyperactiv-
ity, and inappropriate speech. The ABC was administered
immediately prior to beginning the study (to determine
baseline scores) and immediately after finishing 40 ses-
sions. Lower scores on the ABC indicate lower autism
severity.
The ATEC is a questionnaire developed by the Autism
Research Institute to evaluate treatment efficacy in indi-
viduals with autism. It consists of four subscales: Speech/
Language/Communication, Sociability, Sensory/Cogni-
tive Awareness, and Health/Physical/Behavior. The scores
are weighted according to the response and the corre-
sponding subscale. The higher the subscale and total
scores, the more impaired the subject. A split-half reliabil-
ity analysis on 1,358 checklists indicated high internal
consistency among the questions within each subscale
[40]. The ATEC is designed to allow evaluators to assess
Table 1: Initial characteristics of children in the treatment and control groups
Treatment Control Comparison between groups (p-value)
Age 4.97 ± 1.29 4.86 ± 1.13 0.7288*
Male 30/33 22/29 0.1672**
Use of nutritional supplements 23/33 20/29 0.9999**
Use of medications 16/33 10/29 0.3915**
Applied Behavioral Analysis Therapy 15/33 11/29 0.733**
ABC Total Score 55.2 ± 28.7 53.3 ± 24.0 0.7843*
ABC Irritability 13.2 ± 9.5 12.2 ± 7.9 0.6714*
ABC Social Withdrawal 10.5 ± 6.9 11.2 ± 6.9 0.7048*
ABC Stereotypy 7.5 ± 4.9 6.2 ± 4.7 0.3205*
ABC Hyperactivity 20.7 ± 9.9 20.1 ± 8.2 0.8279*
ABC Speech 3.4 ± 3.1 3.6 ± 3.6 0.8567*
ATEC Total Score 75.3 ± 19.5 75.6 ± 21.0 0.9592*
ATEC Speech/Language/Communication 16.3 ± 5.0 15.9 ± 6.1 0.7958*
ATEC Sociability 17.4 ± 6.6 17.8 ± 6.2 0.849*
ATEC Sensory/Cognitive Awareness 18.1 ± 5.2 19.6 ± 5.6 0.3676*
ATEC Health/Physical/Behavior 23.5 ± 11.5 22.4 ± 8.3 0.72*
** Chi-square test with Yates' correction or Fisher's exact test.
* Student's t testBMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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outcomes of certain treatments commonly used in indi-
viduals with autism. In this study, scores were calculated
for the total score and the four separate subscales. The
ATEC was administered immediately prior to beginning
the study (to determine baseline scores) and immediately
after finishing 40 sessions. Due to an administration
error, the baseline ATEC was not performed at one of the
study centers, and thus data was available for analysis for
23 children in the treatment group and 21 children in the
control group.
Scores for the CGI scale were obtained immediately after
40 sessions. The CGI scale gives an impression of global
changes in certain areas for each child compared to base-
line [41]. A total score for change in overall functioning
was rated by a parent or primary caregiver and separately
by the treating physician (the same physician who ini-
tially evaluated the child) using the following ratings: 1
("very much improved"), 2 ("much improved"), 3 ("min-
imally improved"), 4 ("no change"), 5 ("minimally
worse"), 6 ("much worse"), and 7 ("very much worse").
Children who received a score of "very much improved"
or "much improved" on the physician CGI overall func-
tioning score were considered to be "good responders" to
treatment. Data was also collected from parents and phy-
sicians as to whether or not there were improvements in
the following CGI subscales: receptive language, expres-
sive language, sleep pattern, attention span, activity level,
bowel movement pattern, self-stimulatory behavior,
social awareness/alertness, social interaction, play skills,
self-injurious behavior, eye contact, mood, anxiety level,
aggression, general health, gross motor skills, and fine
motor skills.
Analysis
All data were prospectively collected and analyzed using
StatsDirect statistical software (version 2.7.2) and are pre-
sented as mean ± SEM (standard error of the mean). Data
analysis was based on an intention-to-treat approach on
all participants who finished more than one treatment or
control session.
Power Calculations
Because this was the first controlled study of its kind,
power calculations were based on the closest comparable
study that had outcome data available at the time of this
study design [17]. Analysis of this data demonstrated a
medium to large effect size, depending on the scale exam-
ined (Cohen's d = 0.44 to 0.77) [42]. Using the most con-
servative effect size (d = 0.44), a power calculation using
G*Power 3 [43] indicated that a total sample of 43 chil-
dren would achieve a power of 80% with alpha set at 0.05
(two-tailed).
Planned Comparisons
Planned group comparisons were performed on the pri-
mary outcome measures. The normal distribution of data
was checked using the Kolmogorov-Smirnov test. In
parameters with normal distribution, comparisons were
analyzed using the Student's t test. When normality was
not present and equal variance could not be assumed,
nonparametric tests (Mann-Whitney and Wilcoxon
signed rank tests) were used. The Pearson's chi-square (χ2)
test with Yates' correction or the Fisher's exact test (when
subgroups contained less than 10 children) was applied to
assess differences in the percentage of children respond-
ing to treatment in each group. In all analyses, a p-value
less than 0.05 (two-tailed) was considered significant.
Results
Study Sample
The flow of participants throughout the study is depicted
in Figure 1. This study consisted of 52 boys and 10 girls,
which is consistent with the male/female ratio observed in
children with autism [44]. The mean age of all children
was 4.92 ± 1.21 years and was similar (p = ns) in the treat-
ment group (4.97 ± 1.29 years) and the control group
(4.86 ± 1.13 years), see Table 1. There were more girls in
the control group compared to the treatment group, but
this difference was not significant (p = ns). Initial ABC and
ATEC scores were similar in both groups (p = ns). At the
onset of this study, the use of nutritional supplements,
medications, and applied behavioral analysis (ABA) ther-
apy was similar in both groups (p = ns), see Table 1. One-
way analysis of variance (ANOVA) demonstrated no sig-
nificant differences (p = ns) between the six centers that
participated in this study for: age, initial autism severity,
initial ABC total scores, final ABC total scores, initial
ATEC total scores, final ATEC total scores, physician CGI
scores, or parental CGI scores.
Attrition rates during the study were low (see Figure 1). In
the treatment group, two children dropped out of the
study prior to beginning any treatments due to an illness
(one with otitis media, the other with bronchitis).
Another child dropped out before finishing one full treat-
ment due to anxiety in both the child and the parent.
Finally, one child was removed from the study after nine
sessions because asthma symptoms worsened (neither the
parents nor the treating physician felt that the hyperbaric
treatments contributed to the increased asthma symp-
toms, but the child was removed from the study as a pre-
caution); this child's scores performed at time of drop-out
showed mild improvements in behavior (as separately
ranked by both the physician and the parents) and these
scores were included in the intention-to-treat analysis.
The inclusion or exclusion of this child's scores had no sig-
nificant effect on the statistical analysis. The remaining 29
children completed all 40 hyperbaric treatment sessionsBMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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at 1.3 atm and 24% oxygen. Therefore, data from 30 chil-
dren were analyzed in the treatment group.
In the control group, two children dropped out of the
study prior to beginning any treatments (one because of a
death in the family, the other because of the time commit-
ment). One child dropped out prior to finishing one full
treatment due to parental claustrophobia. The remaining
26 children finished all 40 sessions at 1.03 atm and 21%
oxygen.
Outcome Measures
Physician Clinical Global Impression (CGI) Scale
After 40 sessions, the mean physician CGI score for
change in overall functioning compared to baseline signif-
icantly improved (p = 0.0008) by 1.13 points in the treat-
ment group (2.87 ± 0.78, score of 4 = "no change")
compared to 0.38 points in the control group (3.62 ±
0.75), see Figure 2. Furthermore, 9/30 (30%) children in
the treatment group had a "very much improved" or
"much improved" rating compared to 2/26 (7.7%) in the
control group (p = 0.0471). An improvement on the CGI
scale (score of 1, 2, or 3) was noted in 24/30 (80%) chil-
dren in the treatment group compared to 10/26 (38%) in
the control group (p = 0.0024). Conversely, 16/26 (62%)
children in the control group had a "no change" or "min-
imally worse" score (CGI score of 4 or 5) compared to 6/
30 (20%, all 6 had a score of 4) in the treatment group (p
= 0.0024). In the control group, two children received a
score of 5 ("minimally worse"), whereas none received
this score in the treatment group (p = 0.211). No child
received a score worse than 5 in either group. Examination
of the physician CGI subscales demonstrated that more
children improved in the treatment group compared to
the control group in receptive language (p < 0.0001),
social interaction (p = 0.0473), and eye contact (p =
0.0102); a trend towards improvement was also observed
in activity level (p = 0.0545).
Parental Clinical Global Impression (CGI) Scale
The mean parental CGI score for change in overall func-
tioning compared to baseline significantly improved (p =
0.0336) by 1.30 points in the treatment group (2.70 ±
0.81, score of 4 = "no change") compared to 0.83 points
in the control group (3.17 ± 0.73), see Figure 2. A "very
much improved" or "much improved" rating was
Absolute change compared to baseline on the mean CGI overall functioning score in the treatment and control groups as rated  separately by physicians and parents Figure 2
Absolute change compared to baseline on the mean CGI overall functioning score in the treatment and con-
trol groups as rated separately by physicians and parents. * p < 0.001; ** p < 0.05.BMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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observed in 9/30 (30%) children in the treatment group
compared to 4/26 (15%) in the control group (p =
0.2238). Furthermore, 27/30 (90%) children had an
improvement on the CGI scale (score of 1, 2, or 3) in the
treatment group compared to 19/26 (73%) in the control
group (p = 0.1616). A score of "no change" or "minimally
worse" (CGI score of 4 or 5) was reported in 3/30 (10%,
all scored 4) in the treatment group versus 7/26 (27%) in
the control group (p = 0.1616). One child received a score
of 5 ("minimally worse") in the control group compared
to none in the treatment group (p = 0.4643). No child
received a score worse than 5 in either group. Examination
of the parental CGI subscales demonstrated that more
children improved in the treatment group compared to
the control group in receptive language (p = 0.0168) and
eye contact (p = 0.0322).
Examination of the mean CGI score for change in overall
functioning in the treatment group as rated by the physi-
cians compared to the parental ratings demonstrated that
there was no significant difference (p = 0.4716). A signifi-
cant correlation existed between the physician and paren-
tal CGI scales for the treatment group (r = 0.60, p =
0.0005). However, parents of children in the control
group were significantly more likely to rate an improve-
ment on the CGI score for change in overall functioning
than were physicians (p = 0.0245) and therefore the cor-
relation between the physician and parental CGI scales
was not significant (r = 0.27, p = 0.1819).
Aberrant Behavior Checklist (ABC) Scores
In the treatment group, the ABC total score significantly
improved after 40 sessions (p = 0.0118), see Additional
file 1. Improvements in ABC subscales were also observed
in the treatment group for irritability (p = 0.0147), stere-
otypy (p = 0.0124), hyperactivity (p = 0.0211), and
speech (p = 0.0155). No significant improvements were
observed in the control group on the ABC total score or
any of the ABC subscales (p = ns). Analysis of changes in
the ABC total score and subscale scores between the treat-
ment and control groups demonstrated no significant
changes (p = ns), although there was a trend towards
improvement in the treatment group for irritability (p =
0.0976, see Figure 3) and 20/30 (67%) children in the
treatment group had an improvement in irritability com-
pared to 9/26 (35%) in the control group (p = 0.0311).
Autism Treatment Evaluation Checklist (ATEC) Scale
In the treatment group, significant improvements were
observed on the ATEC scale in total score (p = 0.002),
sociability (p = 0.0009), sensory/cognitive awareness (p =
0.0017), and health/physical/behavior (p = 0.0446), see
Additional file 2. In the control group, ATEC improve-
ments were found in total score (p = 0.0385) and sociabil-
ity (p = 0.0134). Analysis of changes in ATEC total score
and subscale scores between the treatment and control
groups showed a significant improvement in sensory/cog-
nitive awareness in the treatment group (p = 0.0367), see
Figure 4. Non-significant improvements in the treatment
group compared to the control group were observed in the
other ATEC subscales (p = ns).
Analysis by age and autism severity
Because we had previously observed that both younger
children and children who had higher initial autism sever-
ity improved more robustly with hyperbaric treatment at
1.3 atm [7,17], two separate sub-analyses of the effects of
age and initial autism severity on the outcome scales used
in this study were performed to determine if a subgroup
could be identified that had a better response to hyper-
baric treatment.
Age
Post-hoc analysis of children in the treatment group dem-
onstrated a better improvement on the ABC total score in
children who were over age 5 compared to those age 5 and
under (p = 0.0482). Comparison of children who were
over age 5 in the treatment and control groups demon-
strated that children in the treatment group had signifi-
cantly better improvements on the ABC in irritability (p =
0.0149), social withdrawal (p = 0.0086), and stereotypy
(p = 0.0434). There was no significant difference in ABC
scores between the treatment and control groups for chil-
dren age 5 and younger (p = ns). When examining the
ATEC scale, comparison of children who were over age 5
between the treatment and control groups demonstrated
that children in the treatment group had significantly bet-
ter improvements in sociability (p = 0.0095) and sensory/
cognitive awareness (p = 0.0384). No significant differ-
ence between the two groups was observed for children
age 5 and younger on the ATEC scale (p = ns). No signifi-
cant age effect (p = ns) was observed between the treat-
ment and control groups on the parental or physician CGI
scales.
Autism severity
Post-hoc analysis of children in the treatment group dem-
onstrated that those who had an initial ADOS score below
the 50th percentile for all children (less initial autism
severity) had similar improvements in ABC total score
and subscales compared to children with an initial ADOS
score above the 50th percentile (p = ns). However, com-
parison of children in the treatment group and the control
group who had an initial ADOS score below the 50th per-
centile (less autism severity) demonstrated that the chil-
dren in the treatment group had significantly better
improvements in ABC irritability (p = 0.0348) and ABC
stereotypy (p = 0.0359). There was no significant differ-
ence in ABC scores between the treatment and control
groups for children with an initial ADOS score above theBMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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50th percentile (p = ns). When examining the ATEC scale,
comparison of children in the treatment group and the
control group with an initial ADOS score below the 50th
percentile demonstrated a significantly better improve-
ment in the treatment group in sociability (p = 0.0333).
No significant difference between groups was observed for
children with an initial ADOS score above the 50th percen-
tile (p = ns). No significant effect (p = ns) was observed for
autism severity between the treatment and control groups
on the parental or physician CGI scales.
Adverse events and tolerance
Hyperbaric treatment in this study was safe and well-tol-
erated. In the treatment group, one child developed both
urinary frequency (urinalysis was normal) and a skin rash
that the treating physician thought was yeast-related. As
previously described, one child had worsening of asthma
symptoms after nine treatment sessions and was removed
from the study, and another child had anxiety and
dropped out of the study before finishing one full treat-
ment. None of the children in the treatment group
received a score worse than 4 ("no change") on the physi-
cian or parental CGI for change in overall functioning. In
the control group, one child developed abdominal disten-
sion and diarrhea during the study, but was able to com-
plete the study. Another child in the control group had
worsening of eczema during the study. No other adverse
events including barotrauma or seizures were observed in
either group.
Discussion
To our knowledge, this trial represents the first controlled
study of hyperbaric treatment in children with autism.
Previous studies examining this treatment in autism have
described improvements that could have been due, in
part, to a participation (placebo) effect. The results of
uncontrolled studies in autism should be interpreted with
caution, especially since some randomized, double-blind,
placebo-controlled studies in individuals with autism
have reported relatively high improvement rates in the
placebo group. For example, one prospective study com-
paring a single dose of IV secretin to a placebo found that
30% of the children receiving the placebo had a signifi-
cant improvement immediately after the infusion [45].
Another prospective study comparing daily treatment
with amantadine to a placebo over a 4-week period found
a mean placebo response rate of 37% [46]. In the current
study, 80% of children in the hyperbaric treatment group
Changes compared to baseline on the ABC total score and subscales (percentage change) in the treatment and control groups Figure 3
Changes compared to baseline on the ABC total score and subscales (percentage change) in the treatment 
and control groups. *** p < 0.1.BMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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had an improvement on the CGI scale for change in over-
all functioning as rated by blinded physicians; however,
38% of children in the control group were also rated as
improved. This 38% improvement rate in the control
group may have occurred because these children received
a very low level of hyperbaric pressure (1.03 atm with
short increases to 1.1 atm), and therefore, strictly speak-
ing, this pressure did not represent a true placebo-control
group. Hyperbaric pressure as low as 20 mmHg (approxi-
mately 1.03 atm) has been shown to decrease in vitro pro-
inflammatory cytokine release (including IL-1beta) from
human monocytes and macrophages [47]. Some children
with ASD have elevations in certain pro-inflammatory
cytokines, including IL-1beta [32,48]. Therefore, some of
the improvements observed in the control group could
have been due to the slight hyperbaric pressure received.
Because the control group experienced pressure condi-
tions closer to those of the treatment group than a true
placebo (e.g., 1.00 atm and 21% oxygen) would have pro-
vided, the difference in clinical outcomes between the
treatment and control groups may have been less signifi-
cant than what would have been observed with a placebo.
However, a true placebo could not have been used with
this study design because some degree of hyperbaric pres-
sure was needed to mimic hyperbaric treatment at 1.3
atm, otherwise blinding of the group assignment would
have not been possible. A pressure of 1.03 atm (with short
increases to 1.1 atm) was chosen for the control group
because testing performed prior to the study indicated
that this pressure was the lowest that could be given and
still effectively simulate, from the perspective of the
blinded parents and children, hyperbaric treatment at 1.3
atm. The blinding procedure in this study appeared to be
adequate because there was no significant difference
between the two groups in the ability of parents to cor-
rectly guess the group assignment of their child. Further-
more, 73% of parents of children in the control group
rated their child as improved on the CGI scale which also
suggests that the blinding procedure was adequate,
because if parents thought that their child was in the con-
trol group, they probably would have been less likely to
rate an improvement after treatment. In the hyperbaric
treatment group, parental CGI scores significantly corre-
lated with physician CGI scores (r = 0.60, p = 0.0005)
which strengthens the CGI results in this group. In the
control group, the parents were significantly more likely
Changes compared to baseline on the ATEC total score and subscales (percentage change) in the treatment and control  groups Figure 4
Changes compared to baseline on the ATEC total score and subscales (percentage change) in the treatment 
and control groups. ** p < 0.05.BMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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to rate their child as improved on the CGI scale compared
to the physicians (p = 0.0245) and therefore the parental
and physician CGI scales did not significantly correlate (r
= 0.27, p = 0.1819). This finding further suggests that the
blinding procedure was adequate in this study and also
demonstrates evidence of a participation effect in the con-
trol group.
In this trial, the use of hyperbaric treatment at 1.3 atm was
well-tolerated and confirmed previous reports of safety.
This study also demonstrated clinical improvements that
were similar to previous uncontrolled studies of hyper-
baric treatment in children with autism [7,17,21,22,35].
The findings of this study are significantly strengthened
because of the presence of a control group which previous
hyperbaric treatment studies in autism lacked, and also
because of the use of six separate centers which should
have minimized potential bias, especially since there were
no significant differences between study sites in age, ini-
tial autism severity, and initial and final scores on all of
the scales used in this study. In this current trial, signifi-
cant improvements were observed in several domains
with the use of hyperbaric treatment at 1.3 atm and 24%
oxygen compared to slightly pressurized room air, includ-
ing overall functioning, receptive language, social interac-
tion, eye contact, and sensory/cognitive awareness. The
reason for these different areas of improvement is not
clear. The mechanism of action of hyperbaric treatment in
autism is not entirely known, although it may act by
diminishing gastrointestinal and cerebral inflammation
and by improving immune dysregulation and cerebral
hypoperfusion [24]. Multiple studies have reported that
these problems are relatively common in children with
autism [26-34].
Cerebral hypoperfusion, especially of the temporal lobes,
is a very common finding in children with autism com-
pared to typically-developing children, affecting up to
75% [28,49]. This hypoperfusion is an indirect measure of
diminished brain activity [28] because cerebral blood
flow is normally tightly coupled to brain metabolic rate
and function [50,51]. Several studies have reported that
the anatomical location of cerebral hypoperfusion signif-
icantly correlates with certain autistic behaviors [24]. For
example, in a study of 30 individuals with autism com-
pared to 14 non-autistic individuals, hypoperfusion of the
thalamus as measured by Single Photon Emission Com-
puted Tomography (SPECT) was observed in the autism
group and significantly correlated (r = 0.42, p < 0.01) with
repetitive behaviors and unusual sensory interests [52]. In
another SPECT study of 23 children with autism com-
pared to 26 non-autistic children, hypoperfusion of the
right medial temporal lobes was found in the autism
group and was correlated with obsessive desire for same-
ness (p < 0.001), and hypoperfusion of the medial pre-
frontal cortex and anterior cingulate gyrus was associated
with impairments in social interaction and communica-
tion (p < 0.001) [27]. Furthermore, two SPECT studies in
individuals with autism have reported that cerebral
hypoperfusion significantly worsens with increasing age
[53,54]. In one of these studies, hypoperfusion of brain
areas that controlled speech (left temporal lobe and fron-
tal areas) significantly worsened with increasing age (p <
0.001) and was associated with deficits in language for-
mation and "subsequently prevent [ed] development of
true verbal fluency and development in the temporal and
frontal areas associated with speech and communication"
[54]. Furthermore, in another study of 45 children with
autism, children with the highest degree of left temporal
lobe hypoperfusion, as measured by Positron Emission
Tomography (PET), also had the most severe autistic
behavior [55].
The cause of cerebral hypoperfusion in children with
autism is not known. Several studies have described
apparent vascular-associated cerebral inflammation in
children with autism compared to controls including
perivascular macrophage and microglia accumulation in
post-mortem autistic brain samples [33] as well as the
presence of serum IgM and IgG autoantibodies that bind
to small blood vessels in the brain in about 30% of chil-
dren [26,56]. These findings could be consistent with a
cerebral vasculitis [24]. Elevated urinary levels of 8-iso-
prostane-F2α have also been reported in some children
with autism [57]. In some studies, this isoprostane eleva-
tion has been shown to cause in vivo vasoconstriction and
increase the aggregation of platelets [58]. Furthermore,
elevations in 2,3-dinor-thromboxane B2 (associated with
increased platelet activation) and 6-keto-prostaglandin
F1α  (a marker of endothelium activation) have been
described in some children with autism [59]. These
inflammatory-related findings could contribute to the cer-
ebral hypoperfusion described in autism [24].
Cerebral hypoperfusion is associated with hypoxia [24]
and several studies in children with ASD have reported
evidence of cerebral hypoxia, as measured by a reduction
in brain Bcl-2 and an increase in brain p53 [60-63]. Ele-
vated p53 is induced by hypoxia [64] and a decrease in
Bcl-2 is associated with increased apoptosis provoked by
hypoxia [65]. Hypoxia leads to higher brain concentra-
tions of hypoxia-inducible factor 1α (HIF-1α) [66]. An
increase in HIF-1α causes an increase in inflammation,
including redness and swelling of tissues, and the attrac-
tion of lymphocytes [66]. HIF-1α is essential for inflam-
mation mediated by myeloid cells [67]. In fact, in one
study, rats that were null for HIF-1α demonstrated almost
complete inhibition of the inflammatory response [68].
HIF-1α is responsible for angiogenesis that is secondary to
hypoxia [68,69] and also induces Vascular EndothelialBMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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Growth Factor (VEGF), which increases the permeability
of blood vessels [66] and causes tissue edema. Evidence of
cerebral edema in 19 children with autism compared to
20 typically-developing children was suggested by one
recent T2-magnetic resonance imaging (MRI) study [70].
This edema can lead to increased interstitial space
between cells [71] and cause an increase in the distance
that oxygen must diffuse from blood vessels to reach brain
cells and can thus lead to cellular hypoxia [72]. Inflamma-
tion is also associated with blood-brain barrier distur-
bances which can further increase cerebral edema [24].
Chronic inflammation is commonly associated with the
infiltration of polymorphonuclear neutrophils and other
immune cells, along with the cytokines that are released
by these cells. This causes an increase in local oxygen
usage due to the elevated oxygen requirements created by
these newly infiltrated cells. Yet, at the same time, inflam-
mation causes reduced oxygen extraction by normal cells
[73]. For instance, in one study, elevated markers of
inflammation (including IL-6, tumor necrosis factor
receptors 1 and 2, and high-sensitivity C-reactive protein)
were significantly correlated with decreased maximum
oxygen uptake at peak exercise (VO2max) in patients with
known or suspected coronary artery disease [74]. There-
fore, inflammation prevents maximal uptake of oxygen by
cells. Inflammation also increases oxidative stress and can
cause neutrophils to become more adherent and attach to
vessel walls [75]. This infiltration and increased adherence
of inflammatory cells can contribute to brain injury by
decreasing microvascular blood flow, causing thrombosis,
and increasing the production of free radicals [76]. Hyper-
baric treatment can overcome the effects of cerebral
hypoperfusion and hypoxia by: increasing the plasma
oxygen tension which transfers more oxygen into tissue,
including the brain [77,78], decreasing cerebral edema
[79], inhibiting the expression of HIF-1α and its target
genes [80], and by causing angiogenesis over time [18].
Several case reports in children with autism have
described improved cerebral perfusion after hyperbaric
treatment at 1.3 atm, as measured by post-hyperbaric
treatment SPECT scans compared to pre-hyperbaric
SPECT scans [21,22]. If the hypoperfusion in children
with autism is related to cerebral inflammation, then
hyperbaric treatment could potentially improve cerebral
perfusion by decreasing this inflammation [24]. Hyper-
baric treatment possesses strong anti-inflammatory prop-
erties [18-20] and has been shown to significantly
decrease neuroinflammation [81] as well as cerebral
edema and blood-brain barrier damage in animal models
[79]. At 1.3 atm, hyperbaric treatment decreased a marker
of inflammation (C-reactive protein) in one study of chil-
dren with autism [7]. It is unknown if any of the improve-
ments observed in this study were mediated through an
improvement in cerebral hypoperfusion and/or a decrease
in cerebral inflammation as this study was not designed to
examine these possibilities. However, since cerebral
hypoperfusion is relatively common [28,49] and can be
diffuse in location in children with autism [82,83], and
the anatomical location of hypoperfusion significantly
correlates with certain autistic behaviors [27,52,54], then
improving hypoperfused brain areas with hyperbaric
treatment could account for the different areas of
improvement observed in this study.
Our previous studies suggested children who were
younger and those who had higher initial autism severity
responded more robustly to hyperbaric treatment [7,17].
However, these studies were small and uncontrolled, and
thus we analyzed these two parameters (age and autism
severity) in this study with a post-hoc analysis. An inter-
esting finding from this current study was that children
who were over age 5 had significantly better improve-
ments on the ABC total score with hyperbaric treatment at
1.3 atm compared to younger children (p = 0.0482).
Given the fact that older children with autism generally
have a higher degree of cerebral hypoperfusion compared
to younger children [53,54] and that hyperbaric treatment
can improve cerebral hypoperfusion [21,22], these factors
could have accounted for the age findings observed in this
study. Additional studies examining the use of hyperbaric
treatment in children with autism that also incorporate
SPECT or PET scans to measure changes in cerebral blood
flow might be helpful in further delineating these possi-
bilities. Moreover, children who had lower initial autism
severity also had the most improvements with hyperbaric
treatment in this study. The reason for this finding is not
known, but may be due to greater levels of oxidative stress
and other metabolic problems recently described in chil-
dren with higher autism severity compared to those with
lower severity [84].
Because this study was not designed to measure the long-
term outcomes of hyperbaric treatment in children with
autism, additional studies are needed to determine if the
significant improvements observed in this study last
beyond the study period. It is possible that ongoing treat-
ments would be necessary to maintain the improvements
observed, but this study was not designed to examine that
possibility. Our clinical observations in children with
autism suggest that additional hyperbaric treatments
beyond 40 total sessions can lead to additional improve-
ments; however, further studies are needed to formally
validate these observations. Recently, several companies
have started producing and marketing portable hyper-
baric chambers that are approved by the U.S. Food and
Drug Administration (FDA) for home use and are able to
supply the hyperbaric treatment parameters used in this
study. Therefore, the widespread and long-term use of this
potential treatment is feasible and not necessarily costlyBMC Pediatrics 2009, 9:21 http://www.biomedcentral.com/1471-2431/9/21
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(on a per treatment basis). Finally, this study was not
designed to determine if higher hyperbaric treatment
parameters (higher atmospheric pressure and oxygen lev-
els, which can only be provided in a clinic setting) would
lead to better or more long-lasting results. Additional
studies are needed to investigate that possibility.
Conclusion
Given the positive findings of this study, and the shortage
of proven treatments for individuals with autism, parents
who pursue hyperbaric treatment for their child with
autism can be assured that it is a safe treatment modality
at the pressure used in this study (1.3 atm), and that it
may improve certain autistic behaviors. Further studies
are needed by other investigators to confirm these find-
ings; we are aware of several other planned or ongoing
studies of hyperbaric treatment in children with autism.
However, in light of the positive results of this study and
those of several previous studies [7,17,21,22,35], the use
of hyperbaric treatment appears to be a promising treat-
ment for children with autism.
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